Olezarsen Sodium — Active Pharmaceutical Ingredient

Olezarsen Sodium is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: SOLUTION. Routes: SUBCUTANEOUS.

Drug Ingredients A–Z 1 min read
This content is for informational purposes only. Always consult a healthcare professional.

Olezarsen Sodium (1 brand name, 1 dosage form, 1 route)

Available dosage forms: SOLUTION.

Routes of administration: SUBCUTANEOUS.

Brand Names

  • TRYNGOLZA (AUTOINJECTOR)

Indications and Usage

TRYNGOLZA ®is indicated as an adjunct to diet: To reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). To reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL).

Contraindications

TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to olezarsen or any of the excipients in TRYNGOLZA. Hypersensitivity reactions, including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias, requiring medical treatment have occurred [see Warnings and Precautions (5.1)] .

Adverse Reactions

The following clinically significant adverse reactions are discussed elsewhere in the labeling: Hypersensitivity Reactions [ see Warnings and Precautions (5.1) ] Liver Enzyme Abnormalities [see Warnings and Precautions (5.2)]

Mechanism of Action

Olezarsen is an ASO-GalNAc 3 conjugate that binds to apoC-III mRNA leading to mRNA degradation and resulting in a reduction of serum apoC-III protein. Reduction of apoC-III protein leads to increased clearance of plasma TG and very low-density lipoprotein (VLDL).

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.